High Tech Pharm Co., Ltd. (KOSDAQ:106190)
South Korea · Delayed Price · Currency is KRW 15,420
-480 (-3.02%)
At close: Mar 19, 2026
High Tech Pharm Revenue
In the year 2025, High Tech Pharm had annual revenue of 70.18B KRW, down -9.46%. High Tech Pharm had revenue of 14.04B in the quarter ending December 31, 2025, a decrease of -27.84%.
Revenue
70.18B
Revenue Growth
-9.46%
P/S Ratio
2.93
Revenue / Employee
1.08B
Employees
65
Market Cap
205.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.18B | -7.33B | -9.46% |
| Dec 31, 2024 | 77.51B | 740.98M | 0.97% |
| Dec 31, 2023 | 76.77B | -26.18B | -25.43% |
| Dec 31, 2022 | 102.95B | 29.66B | 40.47% |
| Dec 31, 2021 | 73.29B | -1.17B | -1.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 385.76B |
| DongKoo Bio & Pharma | 238.39B |
| Kyung Dong Pharmaceutical | 193.64B |
| GREEN CROSS WellBeing | 151.06B |
| HYUNDAI BIOLAND | 130.51B |
| KOREA PHARMA | 90.11B |
| OPTUS Pharmaceutical | 87.16B |
| Vivozon Pharmaceutical | 66.40B |